Immunotherapy as new approach to battle senescent cells
New study have taken a CAR-T immunotherapy approach to removing senescent cells.
Identified urokinase-type plasminogen activator receptor (uPAR), as suitable target.
uPar is a cell-surface protein widely activated in senescent cells.
CAR T cells that target uPAR extend the survival of mice with lung adenocarcinoma.
These are mice that are treated with a senescence-inducing combination of drugs.
Also, it restored tissue homeostasis in mice with liver fibrosis induced chemically or by diet.
Results establish therapeutic potential of senolytic CAR T cells for senescence-associated diseases.
Researchers from Memorial Sloan Kettering Cancer Center, published in Nature.
Mentioned in this article:
Memorial Sloan Kettering Cancer Center - Cancer treatment and research institution in New York City